These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 20427293)

  • 1. Comment on: A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis.
    Herrick AL; Lunt M; Silman AJ; Denton CP
    Rheumatology (Oxford); 2010 Aug; 49(8):1607-8; author reply 1608. PubMed ID: 20427293
    [No Abstract]   [Full Text] [Related]  

  • 2. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis.
    Derk CT; Grace E; Shenin M; Naik M; Schulz S; Xiong W
    Rheumatology (Oxford); 2009 Dec; 48(12):1595-9. PubMed ID: 19846575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolate mofetil for interstitial lung disease in scleroderma.
    Plastiras SC; Vlachoyiannopoulos PG; Tzelepis GE
    Rheumatology (Oxford); 2006 Dec; 45(12):1572. PubMed ID: 16998235
    [No Abstract]   [Full Text] [Related]  

  • 4. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset.
    Mendoza FA; Nagle SJ; Lee JB; Jimenez SA
    J Rheumatol; 2012 Jun; 39(6):1241-7. PubMed ID: 22467932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis.
    Nihtyanova SI; Brough GM; Black CM; Denton CP
    Rheumatology (Oxford); 2007 Mar; 46(3):442-5. PubMed ID: 16899504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis.
    Le EN; Wigley FM; Shah AA; Boin F; Hummers LK
    Ann Rheum Dis; 2011 Jun; 70(6):1104-7. PubMed ID: 21378404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upfront Combination Therapy With Rituximab and Mycophenolate Mofetil for Progressive Systemic Sclerosis.
    Rimar D; Rosner I; Slobodin G
    J Rheumatol; 2021 Feb; 48(2):304-305. PubMed ID: 33060315
    [No Abstract]   [Full Text] [Related]  

  • 8. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis.
    Lankarani KB
    Aliment Pharmacol Ther; 2005 May; 21(10):1279-80; author reply 1280. PubMed ID: 15882250
    [No Abstract]   [Full Text] [Related]  

  • 9. Mycophenolate mofetil in the treatment of lupus nephritis--7 years on.
    Chan TM
    Lupus; 2008 Jul; 17(7):617-21. PubMed ID: 18625633
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS).
    Herrick AL; Pan X; Peytrignet S; Lunt M; Hesselstrand R; Mouthon L; Silman A; Brown E; Czirják L; Distler JHW; Distler O; Fligelstone K; Gregory WJ; Ochiel R; Vonk M; Ancuţa C; Ong VH; Farge D; Hudson M; Matucci-Cerinic M; Balbir-Gurman A; Midtvedt Ø; Jordan AC; Jobanputra P; Stevens W; Moinzadeh P; Hall FC; Agard C; Anderson ME; Diot E; Madhok R; Akil M; Buch MH; Chung L; Damjanov N; Gunawardena H; Lanyon P; Ahmad Y; Chakravarty K; Jacobsen S; MacGregor AJ; McHugh N; Müller-Ladner U; Riemekasten G; Becker M; Roddy J; Carreira PE; Fauchais AL; Hachulla E; Hamilton J; İnanç M; McLaren JS; van Laar JM; Pathare S; Proudman S; Rudin A; Sahhar J; Coppere B; Serratrice C; Sheeran T; Veale DJ; Grange C; Trad GS; Denton CP
    Ann Rheum Dis; 2017 Jul; 76(7):1207-1218. PubMed ID: 28188239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease.
    Liossis SN; Bounas A; Andonopoulos AP
    Rheumatology (Oxford); 2006 Aug; 45(8):1005-8. PubMed ID: 16490756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cryoglobulinemic vasculitis in systemic sclerosis successfully treated with mycophenolate mofetil.
    Ostojic P
    Rheumatol Int; 2014 Jan; 34(1):145-7. PubMed ID: 23271426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil or intravenous cyclophosphamide in lupus nephritis.
    Karassa FB
    N Engl J Med; 2006 Feb; 354(7):764-5; author reply 764-5. PubMed ID: 16481648
    [No Abstract]   [Full Text] [Related]  

  • 14. Mycophenolate mofetil in IgA nephropathy.
    Sepe V; Rossi N; Adamo G; Dal Canton A
    Kidney Int; 2004 Oct; 66(4):1713; author reply 1713-4. PubMed ID: 15458475
    [No Abstract]   [Full Text] [Related]  

  • 15. Mycophenolate mofetil for chronic inflammatory demyelinating polyradiculoneuropathy: An open-label study.
    Radziwill AJ; Schweikert K; Kuntzer T; Fuhr P; Steck AJ
    Eur Neurol; 2006; 56(1):37-8. PubMed ID: 16914929
    [No Abstract]   [Full Text] [Related]  

  • 16. Rationale for trials of long-term mycophenolate mofetil therapy for primary biliary cirrhosis.
    Jones EA
    Hepatology; 2002 Feb; 35(2):258-62. PubMed ID: 11826397
    [No Abstract]   [Full Text] [Related]  

  • 17. Mycophenolate mofetil treatment of myasthenia gravis.
    Cahoon WD; Kockler DR
    Ann Pharmacother; 2006 Feb; 40(2):295-8. PubMed ID: 16403848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate mofetil monotherapy in patients who have had kidney transplants.
    Land W
    Transplantation; 2003 Jun; 75(12):2159. PubMed ID: 12829933
    [No Abstract]   [Full Text] [Related]  

  • 19. Meta-analysis of mycophenolate mofetil in IgA nephropathy.
    Navaneethan SD; Viswanathan G; Strippoli GF
    Nephrology (Carlton); 2008 Feb; 13(1):90. PubMed ID: 18199113
    [No Abstract]   [Full Text] [Related]  

  • 20. Evidence for efficacy of a drug widely used without authorisation in multiple sclerosis: mycophenolate mofetil.
    Kira J
    J Neurol Neurosurg Psychiatry; 2014 Mar; 85(3):246. PubMed ID: 23761914
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.